Research programme: monoclonal antibodies - Eutilex

Drug Profile

Research programme: monoclonal antibodies - Eutilex

Alternative Names: EU-101; EU-102; EU-103

Latest Information Update: 10 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eutilex
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD137 antigen agonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 06 Nov 2017 EU 101 licensed to Zhejiang Huahai Pharmaceutical for development and commercialisation in China, Taiwan, Hong Kong and Macau
  • 06 Nov 2017 Preclinical trials in Cancer in South Korea (unspecified route) before November 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top